Edition:
India

Chimerix Inc (CMRX.OQ)

CMRX.OQ on NASDAQ Stock Exchange Global Market

4.94USD
9:51pm IST
Change (% chg)

$0.01 (+0.20%)
Prev Close
$4.93
Open
$4.90
Day's High
$4.97
Day's Low
$4.83
Volume
32,814
Avg. Vol
76,719
52-wk High
$6.63
52-wk Low
$4.18

Latest Key Developments (Source: Significant Developments)

Chimerix Inc entered into agreement with Cowen and Co
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Chimerix Inc :On November 8, 2017, co entered into an at market issuance, or ATM, sales agreement with Cowen and Company LLC - SEC filing​.Under agreement co may offer and sell shares of its common stock, $0.001 per share, having aggregate gross proceeds of up to $75 million​.  Full Article

Chimerix reports Q3 loss of $0.37/shr
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Chimerix Inc :Chimerix announces third quarter 2017 financial results.Q3 loss per share $0.37.Q3 revenue $900,000 versus I/B/E/S view $850,000.Q3 earnings per share view $-0.43 -- Thomson Reuters I/B/E/S.  Full Article

Chimerix Q2 loss per share $0.39
Monday, 8 Aug 2016 

Chimerix Inc : Chimerix announces second quarter 2016 financial results . Q2 earnings per share view $-0.51 -- Thomson Reuters I/B/E/S .Q2 revenue $1.8 million versus I/B/E/S view $2 million.  Full Article

Chimerix Q1 loss per share $0.57
Monday, 9 May 2016 

Chimerix Inc : Chimerix Announces Top-Line Interim AdVise Data and First Quarter 2016 Financial Results . Q1 loss per share $0.57 . Q1 revenue $1.2 million . Q1 revenue view $2.8 million -- Thomson Reuters I/B/E/S .Q1 earnings per share view $-0.66 -- Thomson Reuters I/B/E/S.  Full Article

Chimerix Inc presents positive results from brincidofovir pivotal study in animal model for smallpox
Tuesday, 9 Feb 2016 

Chimerix Inc:Presents positive results from brincidofovir pivotal study in animal model for smallpox.Study met its primary endpoint of clinically and statistically significant (p<0.05) reduction in mortality for brincidofovir-treated animals compared with animals that received placebo.Final data from the rabbitpox study together with efficacy data from a mouse model of smallpox will be submitted to the FDA for discussion of next steps.  Full Article

BRIEF-Chimerix Initiates Adapt Study For Oral Brincidofovir

* CHIMERIX INITIATES ADAPT STUDY FOR ORAL BRINCIDOFOVIR AND ADVANCES IV BRINCIDOFOVIR TO PATIENT STUDIES Source text for Eikon: Further company coverage: